News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
510,657 Results
Type
Article (43819)
Company Profile (123)
Press Release (466715)
Section
Business (144248)
Career Advice (2365)
Deals (27852)
Drug Delivery (97)
Drug Development (67490)
Employer Resources (147)
FDA (15437)
Job Trends (11895)
News (262104)
Policy (29509)
Tag
Academia (2280)
Africa (665)
Alliances (35595)
Alzheimer's disease (1193)
Antibody-drug conjugate (ADC) (61)
Approvals (15351)
Arizona (120)
Artificial intelligence (56)
Asia (30180)
Australia (5264)
Bankruptcy (299)
Best Places to Work (8830)
Biosimilars (67)
Biotechnology (74)
C2C Services and Suppliers (51923)
California (1446)
Canada (647)
Cancer (366)
Career advice (1972)
Cell therapy (116)
China (98)
Clinical research (52525)
Collaboration (104)
Colorado (56)
Compensation (64)
Connecticut (63)
COVID-19 (2492)
Cystic fibrosis (67)
Data (187)
Diabetes (75)
Diagnostics (4934)
Drug pricing (77)
Earnings (55992)
Employer resources (132)
Europe (72955)
Events (72934)
Executive appointments (103)
FDA (15612)
Florida (216)
Funding (90)
Gene therapy (92)
GLP-1 (566)
Government (3750)
Healthcare (14621)
Hotbed/Location (337111)
Illinois (171)
Indiana (106)
Infectious disease (2518)
Inflammatory bowel disease (80)
Interviews (441)
IPO (13688)
Job creations (3145)
Job search strategy (1654)
Kansas (74)
Layoffs (425)
Legal (6872)
Lung cancer (91)
Manufacturing (81)
Maryland (332)
Massachusetts (1204)
Medical device (10930)
Medtech (10933)
Mergers & acquisitions (14020)
Metabolic disorders (262)
Michigan (89)
Minnesota (160)
Neuroscience (1328)
New Jersey (437)
New York (449)
NextGen Class of 2024 (4950)
Non-profit (3146)
North Carolina (519)
Northern California (683)
Obesity (161)
Ohio (78)
Opinion (177)
Patents (64)
Pennsylvania (479)
People (41352)
Phase I (15602)
Phase II (22715)
Phase III (18792)
Pipeline (99)
Policy (60)
Postmarket research (2184)
Preclinical (6304)
Rare diseases (117)
Real estate (4239)
Recruiting (58)
Regulatory (19812)
Research institute (2043)
Resumes & cover letters (396)
South America (1024)
Southern California (597)
Startups (2730)
Texas (176)
United States (6647)
Vaccines (526)
Washington State (209)
Weight loss (155)
Date
Today (94)
Last 7 days (539)
Last 30 days (1889)
Last 365 days (32780)
2024 (22216)
2023 (34981)
2022 (45060)
2021 (48504)
2020 (45512)
2019 (36210)
2018 (27397)
2017 (27806)
2016 (25803)
2015 (27979)
2014 (21775)
2013 (17792)
2012 (18963)
2011 (19381)
2010 (17504)
510,657 Results for "immutep s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Immutep successfully completes institutional placement and institutional component of entitlement offer
Immutep Limited ACN 009 237 889 is pleased to announce the successful completion of its institutional placement and the institutional component of its 1 for 16 pro rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Immutep.
June 5, 2024
·
7 min read
Cancer
Immutep Aces Phase IIb in First-Line Head and Neck Cancer, Eyes Regulatory Path Ahead
Immutep shares jumped nearly 20% on Friday after data showed its LAG-3 therapy—plus Keytruda—elicited strong response rates in head and neck squamous cell carcinoma patients in the front-line setting.
July 12, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
Immutep Limited announces initial encouraging data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha in combination with radiotherapy, a standard-of-care treatment, plus KEYTRUDA® for patients with soft tissue sarcoma.
May 2, 2024
·
5 min read
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer
Immutep Limited announces a License Agreement with Cardiff University granting the Company exclusive rights to develop and commercialise anti-LAG-3 small molecules.
June 25, 2024
·
4 min read
Business
Immutep Quarterly Activities Report Q3 FY24
Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha (efti) and IMP761 for the quarter ended 31 March 2024 (Q3 FY24).
April 29, 2024
·
7 min read
Drug Development
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
Immutep Limited announced that it has entered into a clinical trial collaboration and supply agreement with MSD, through a subsidiary, to evaluate eftilagimod alfa in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® and chemotherapy for the first-line treatment of metastatic non-small cell lung cancer in a pivotal Phase III trial.
June 2, 2024
·
6 min read
Press Releases
Immutep to Participate in Upcoming Investor Conferences
August 7, 2024
·
1 min read
Drug Development
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024
Immutep Limited today announces encouraging efficacy, safety, and pharmacodynamic data from the safety lead-in of the AIPAC-003 Phase II/III trial presented at the European Society for Medical Oncology (ESMO) Breast Cancer 2024 Congress.
May 15, 2024
·
5 min read
Drug Development
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Immutep Limited today announces preliminary topline results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial evaluating eftilagimod alpha (efti) in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma patients (1L HNSCC) with negative PD-L1 expression.
April 24, 2024
·
7 min read
Press Releases
Immutep Quarterly Activities Report Q4 FY24
July 31, 2024
·
13 min read
1 of 51,066
Next